News stories about Hologic (NASDAQ:HOLX) have been trending somewhat positive on Wednesday, Accern Sentiment Analysis reports. Accern identifies positive and negative media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Hologic earned a media sentiment score of 0.24 on Accern’s scale. Accern also assigned press coverage about the medical equipment provider an impact score of 45.2358088658192 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the news stories that may have impacted Accern’s scoring:
- Trading summary of Unusual Activity – Hologic, Inc. (HOLX) – Wall Street Morning (wallstreetmorning.com)
- Hologic, Inc. (NASDAQ:HOLX) – Hot Stock of the Day – Nasdaq Journal (nasdaqjournal.com)
- Hologic (HOLX) Down 4.5% Since Earnings Report: Can It Rebound? (finance.yahoo.com)
- Hologic, Inc. (HOLX) has analyst mean rating score of 1.90 – Nasdaq Fortune (press release) (nasdaqfortune.com)
- “Dancing with the Stars” host and cervical cancer survivor Erin Andrews fights to save lives (finance.yahoo.com)
HOLX has been the subject of several analyst reports. Needham & Company LLC reiterated a “buy” rating and issued a $48.00 target price (up previously from $46.00) on shares of Hologic in a report on Tuesday, December 5th. Goldman Sachs Group upgraded shares of Hologic from a “buy” rating to a “conviction-buy” rating and raised their price objective for the stock from $45.00 to $50.00 in a report on Friday, December 8th. Cowen upgraded shares of Hologic from a “market perform” rating to an “outperform” rating and set a $51.00 target price for the company in a research report on Monday, December 11th. Evercore ISI initiated coverage on shares of Hologic in a research report on Wednesday, January 3rd. They set an “outperform” rating and a $50.00 target price for the company. Finally, Bank of America upgraded shares of Hologic from a “neutral” rating to a “buy” rating and set a $50.00 price objective for the company in a research report on Thursday, January 4th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $48.00.
Hologic (NASDAQ:HOLX) last announced its earnings results on Thursday, February 8th. The medical equipment provider reported $0.55 EPS for the quarter, beating the Zacks’ consensus estimate of $0.50 by $0.05. The firm had revenue of $791.10 million for the quarter, compared to analysts’ expectations of $785.80 million. Hologic had a net margin of 34.53% and a return on equity of 20.07%. The company’s quarterly revenue was up 7.7% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.52 EPS. equities research analysts expect that Hologic will post 2.25 earnings per share for the current year.
In other Hologic news, Director Namal Nawana bought 6,600 shares of the firm’s stock in a transaction on Tuesday, February 13th. The stock was acquired at an average price of $37.88 per share, with a total value of $250,008.00. Following the transaction, the director now owns 6,954 shares in the company, valued at $263,417.52. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 0.88% of the company’s stock.
Hologic Company Profile
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.